Dr. Azita Haddadi

PharmD (Tehran), PhD (Tehran)
Assistant Professor of Pharmacy

301.1, D-Wing, Health Sciences Building
Phone: 306-966-6495
Fax: 306-966-6377
azita.haddadi@usask.ca

Dr. Haddadi joined the College of Pharmacy and Nutrition in July 2010, following positions as Research Associate at the University of Alberta and Senior Scientist at the Quest PharmaTech Inc. in Edmonton. She arrived in Alberta as a Research Scholar in 2003 and completed a three-year Postdoctoral Fellowship there.

Teaching Responsibilities

Pharmaceutics, Vaccine Delivery, Targeted Nanoparticles

Research Interests

Dr. Haddadi’s research program focuses on overcoming the ongoing challenges in cancer therapy. The main emphasis of this research is to develop new biomedical and pharmaceutical nanotechnology strategies to achieve the critical issues in cancer chemo-immunotherapy. Her research activities are in the following areas:

  • Formulation and characterization of polymeric nanomaterials and protein therapeutics
  • siRNA/Oligonucletide delivery in cancer treatment
  • Targeted delivery systems for pharmaceutical applications (topical, iv. or sc. administration)
  • Receptor-mediated nanoparticles for vaccine delivery
  • Receptor-based tumor targeting for chemotherapy

Published Works

Azita Haddadi's publications on PubMed 

Hamdy S, Haddadi A, Shayeganpour A., Samuel J., and Lavasanifar A.; “Activation of antigen specific T cell responses by mannan-decorated PLGA nanoparticles”, Pharmaceutical Research, 2011, in press.

Hamdy S, Haddadi A, Hung RW, Samuel J, and Lavasanifar A. “Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations” Advanced Drug delivery Reviews, 2011, in press.

Alshamsan A, Hamdy S, Haddadi A, Samuel J, Uludag H, El-Kadi A, and Lavasanifar A., STAT3 knockdown in B16 melanoma by si-RNA Lipopolyplexes induces bystander immune response in vitro and in vivo. Translational oncology. 2011, 4: 178-188.

Hamdy S., Haddadi A., Ghotbi Z., Hung RW. and Lavasanifar A.; “ Targeted particles for cancer immunotherapy”, Current Drug Delivery, 2011, 8 (3): 261-273.

Hamdy S, Haddadi A, Shayeganpour A., Alshamsan A., Montazeri Aliabadi HR. and Lavasanifar A.; “The immunosuppressive activity of polymeric micellar formulation of cyclosporine A: in vitro and in vivo studies”, The AAPS Journal, 2011, 13 (2): 159-168.

Hung RW., Hamdy S., Haddadi A., Ghotbi Z. and Lavasanifar A.; “ Targeted particles for imaging of anticancer immune responses”, Current Drug Delivery, 2011, 8 (3): 274-281.

Ghotbi Z., Haddadi A., Hamdy S., Hung R., Samuel J. and Lavasanifar A.; “Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles.”, J Drug Targeting, 2011, 19(4): 281-292.

Alshamsan A., Haddadi A., Hamdy S., Samuel J., El-Kadi A., Uludag H., and Lavasanifar A.; “STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anti-cancer immune response”, Molecular Pharmaceutics, 2010, 7(5): 1643-1654.

Alshamsan A., Haddadi A., Incani V., Samuel J., El-Kadi A., Lavasanifar A. and Uludag H.; “Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine”, Molecular Pharmaceutics, 2009, 6 (1): 121–133.

Haddadi A., Elamanchili P., Lavasanifar A., Das S., Shapiro J. and Samuel J., “Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells”. Journal of Biomedical Material Research, 2008, 84A (4): 885-898.

Haddadi A., Farboud ES., Erfan M., Aboofazeli R.; “Preparation and characterization of w/o and o/w creams containing urea loaded PLGA microspheres”.Journal of Microencapsulation, 2008, 25(6): 379-386.

Das S., Haddadi A., Veniamin S. and Samuel J.; “Delivery of rapamycin-loaded nanopaerticles down regulates ICAM-1 expression and maintains an immunosuppressive profile in human CD34+ progenitor-derived dendritic cells”. Journal of Biomedical Material Research, 2008, 85A(4): 983-992.

Ma Z., Haddadi A., Molavi O., Lavasanifar A., Lai R. and Samuel J., “Micelles of poly(ethylene oxide)-b-poly(e-caprolactone) as vehicles for the solubilization, stabilization and controlled delivery of curcumin”. Journal of Biomedical Material Research, 2008, 86 (2): 300-10

Ma Z., Molavi O., Haddadi A., Lai R., Gossage R. and Lavasanifar A.; “Resveratrol analog trans 3,4,5,4`-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol. Cancer Chemother Pharmacol. 2008,63 (1): 27-35.

Hamdy S., Molavi O., Ma Z., Haddadi A., Alshamsan A., Ghotbi Z., Elhasi S., Samuel J. and Lavasanifar A.; “Co-delivery of cancer associated antigen and Toll like receptor 4 ligand PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity”, Vaccine 2008, 26(39): 5046-5057.

Hamdy S., Haddadi A., Somayaji V., Ruan D. and Samuel J., “The pharmaceutical analysis of synthetic lipid A-based vaccine adjutants in poly (D,L-lactic-co-glycolic acid) nanoparticle formulations”. Journal of Pharmaceutical and Biomedical Analysis, 2007, 44(4): 914-923.

Haddadi A., Farboud ES., Erfan M., Aboofazeli R.; “Preparation and characterization of biodegradable urea loaded microparticles as an approach for transdermal delivery” Journal of Microencapsulation, 2006, 23 (6): 698-712.

Research category keywords

PLGA Nanoparticles, Targeted Delivery, Protein Therapeutics, Targeted Chemotherapy, siRNA/Oligonucletide Delivery, Vaccines